TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial

Necchi, A; Guerrero-Ramos, F; Crispen, PL; Herrera-Imbroda, B; Garje, R; Powles, T; Peyton, CC; Pradere, B; Ku, JH; Shore, N; Bögemann, M; Preston, MA; Xylinas, E; Llano, CSD; Hasan, M; Stitou, H; Bhanvadia, S; Sweiti, H; Psutka, S – 2025 –...

Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes – ANNALS OF ONCOLOGY

Olmos, D; Lorente, D; Alameda, D; Cattrini, C; Romero-Laorden, N; Lozano, R; Lopez-Casas, PP; Jambrina, A; Capone, C; Vanden Broecke, AM; Trevisan, M; Van Sanden, S; Juergens, A; Herrera-Imbroda, B; Castro, E – 2024 – 10.1016/j.annonc.2024.01.011